The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
Advising Australian-based lithium company Liontown Resources Limited on its response to change of control proposals from Albemarle Corporation.
Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary
Advising Parthenon Capital, a financial services & technology focused private equity firm, on its acquisition of Global Payment’s Gaming Services Division, a leading provider of on-site and digital payment processing services to companies in the gaming industry, for $415mm
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
Advising Eisai, a Japanese pharmaceutical company, on the sale of Eisai Distribution, a 100% shares holding logistic subsidiary, to Yasuda Logistics Corporation, a Japanese logistic company conducting total logistic services such as Warehousing, Transportation, delivery and forwarding, and Port transportation business, etc.
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
Advised Liontown Resources, an ASX-listed lithium company focused on the development of the world-class Kathleen Valley Lithium Project, on a lithium spodumene concentrate offtake agreement and A$300m financing facility from Ford Motor Company
Advisor to Syrah Resources, an ASX-listed industrial minerals and technology company, on its US$107mm loan from the U.S. Department of Energy under the Advanced Technology Vehicles Manufacturing loan program to fund the initial expansion of its Vidalia active anode material facility in Louisiana, USA
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
Advised Alteon Health, a portfolio company of New Mountain Capital and national physician-led provider of emergency medicine, hospitalist medicine and post-acute care services, on its sale to U.S. Acute Care Solutions
Advised Akorn Pharmaceuticals, a specialty pharmaceuticals manufacturer and marketer, on the divestiture of its portfolio of branded ophthalmic products to Laboratoires Théa SAS
Advising Mitsui Chemicals, one of the largest Japanese chemical companies, on the acquisition of a 30% stake in Japan Medical Dynamic Marketing, a leading orthopedic medical device manufacturer in Japan, held by NGK SPARK PLUG
Advised MetalX, Inc., a leading ferrous and non-ferrous metal scrap recycling company, on the sale of substantially all of its ferrous scrap processing business to BlueScope Steel Limited, an Australian-listed provider of steel materials, products, systems and technologies
Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"
Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America
Advising the Board of Directors of Score Media and Gaming (“theScore”), a leading digital media and sports betting and technology company, regarding the acquisition of theScore by Penn National Gaming
Advised Australian Unity Funds Management on its successful defence of Australian Unity Healthcare Property Trust, in response to four unsolicited offers from a consortium comprised of NorthWest Healthcare Properties REIT and Singaporean sovereign wealth fund, GIC
Advised DADA Holdings on the sale of its majority stake in New Day Aluminum LLC to Concord Resources Ltd.
Advising Deltalab, a leading Spanish laboratory solutions provider with dedicated manufacturing capacity, on the sale of the company to SCG Packaging Public Company Limited, the largest integrated packaging and paper company in Southeast Asia
Advised VEP Healthcare, a leading, physician-owned provider of clinical management services in emergent and inpatient settings in the United States, on its merger with U.S. Acute Care Solutions
Advised Community Psychiatry, a leading provider of outpatient behavioral health services with a focus on high-quality clinically-driven care, on its acquisition of MindPath Care Centers, deepening its national presence to more than 350 providers across the US